Investor Presentaiton slide image

Investor Presentaiton

47 Investor presentation Full year 2022 Phase 2 trial for CagriSema in people with type 2 diabetes has been successfully completed Exploratory phase 2a trial of CagriSema in T2D Cagrilintide 2.4 mg + semaglutide 2.4 mg Headline trial results Change in HbA1c Change in body weight Mean baseline HbA1c: 8.4% Mean baseline body weight: 106 kg R Cagrilintide 2.4 mg + placebo 1:1:1 Semaglutide 2.4 mg + placebo + + Dose escalation Treatment maintenance 16 weeks 16 weeks Follow up 5 weeks Change from baseline (%) -0.93% ויי ווי -15.6% -1.79% -2.18% Cagrilintide 2.4 mg OW Primary endpoint: Change from baseline (week 0) to week 32 in HbA1c Inclusion criteria (92 people): Type 2 diabetes • HbA1c 7.5-10.0% Metformin +/- SGLT2i BMI ≥27 kg/m2 Semaglutide 2.4 mg OW CagriSema (2.4 mg semaglutide and 2.4 mg cagrilintide) In the trial, CagriSema appeared to have a safe and well-tolerated profile Note: Trial product estimands shown; Trial objective: To compare the effect of co-administered (separate injections) semaglutide and cagrilintide versus semaglutide in subjects with T2D inadequately controlled on metformin with or without SGLT2 inhibitor T2D: Type 2 diabetes, BMI: body mass index; HbA1c: Glycosylated haemoglobin; OW: Once-weekly Novo NordiskⓇ
View entire presentation